ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is providing an update on the usage of its “at the market” equity offering plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering system under which Acasti might issue as well as market from time to time its common shares having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares were marketed at prevailing market prices averaging US$1.0747 a share. No securities were marketed in the facilities of the TSXV or perhaps, to the understanding of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will supply the Company with supplemental freedom in its ongoing review process to explore as well as evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescribed drugs using OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have substantial clinical proof of safety as well as efficacy in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG.
Forward Looking Statements – ACST Stock
Statements of this press release which are not statements of current or historical truth constitute “forward looking information” within the meaning of Canadian securities laws and “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking assertions include known and unknown risks, uncertainties, as well as other unknown components that may result in the actual outcomes of Acasti to be materially different from historical success or as a result of any later outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, people are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak just as of the particular date of this press release. Forward-looking assertions in that press release include, but are not confined to, statements or info concerning Acasti’s strategy, succeeding operations as well as its review of strategic options.
The forward-looking assertions found in this specific press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward-Looking Statements” area in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor area of Acasti’s website at www.acastipharma.com. All forward-looking claims in this press release are made as of the particular date of this particular press release.
ACST Stock – Acasti doesn’t undertake to upgrade any such forward looking statements whether as a consequence of info which is brand new, future events or otherwise, except as called for by law. The forward-looking claims contained herein are also subject generally to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, including Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the usage